Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available.

II. Obtain additional safety information on continuous infusion epoprostenol. III. Obtain additional information on economic resource health consumption.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Collaborator: Baylor College of Medicine
• Treatments: Epoprostenol; Tezosentan

Criteria

PROTOCOL ENTRY CRITERIA:

• Severe primary pulmonary hypertension

• Able to prepare and self-administer medication